Search Results - "Wittenburg, L. A."

Development of a limited‐sampling model for prediction of doxorubicin exposure in dogs by Wittenburg, L. A, Thamm, D. H, Gustafson, D. L

“…Understanding the relationship between drug dose and exposure (pharmacokinetics, PK) and the relationship between exposure and effect (pharmacodynamics) is an…”
Get full text

Limited sampling pharmacokinetics of subcutaneous ondansetron in healthy geriatric cats, cats with chronic kidney disease, and cats with liver disease by Fitzpatrick, R. L., Wittenburg, L. A., Hansen, R. J., Gustafson, D. L., Quimby, J. M.

“…Ondansetron, a 5‐HT3 receptor antagonist, is an effective anti‐emetic in cats. The purpose of this study was to compare pharmacokinetics of subcutaneous (SQ)…”
Get full text

Anti‐inflammatory drugs decrease infection of brain endothelial cells with EHV‐1 in vitro by Goehring, L. S., Brandes, K., Ashton, L. V., Wittenburg, L. A., Olea‐Popelka, F. J., Lunn, D. P., Soboll Hussey, G.

“…Summary Background Equine herpesvirus‐associated myeloencephalopathy is the result of endothelial cell infection of the spinal cord vasculature with equine…”
Get full text

Rat survival to anthrax lethal toxin is likely controlled by a single gene by Nye, S H, Wittenburg, A L, Evans, D L, O'Connor, J A, Roman, R J, Jacob, H J

“…We examined whether survival of different rat strains administered anthrax lethal toxin is genetically determined. A reproducible test population of first…”
Get full text

LBOVI-A-2 by Harrington, Y. A., Korb, S. K., Cozzi, N. V., Nye, S. H., Wittenburg, A. L., Vernon, H. J., Evans, D. L., O'Connor, J. A., Lapczynski, L. H., Dahly‐Vernon, A. J., Baye, J. F., Roman, R. J., Jacob, H. J.

“…BACKGROUND/AIMS Over 90% of drug candidates fail in clinical trials, incurring high costs to the pharmaceutical industry. To address this problem, PhysioGenix…”
Get full text